Ether Oxygen Is Part Of The Chain Patents (Class 514/651)
  • Patent number: 11529441
    Abstract: According to the invention there is provided inter alia a medical device for delivering a paclitaxel to a tissue, the device the device having a coating layer applied to a surface of the device, the coating layer comprising components i), ii) and iii), wherein component i) is a therapeutic agent which is paclitaxel; and component ii) is urea or a pharmaceutically acceptable salt thereof, or a urea derivative or a pharmaceutically acceptable salt thereof; and component iii) is succinic acid, glutaric acid or caffeine, or a pharmaceutically acceptable salt of any one thereof.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: December 20, 2022
    Assignee: W. L. Gore & Associates, Inc.
    Inventors: Per Antoni, Karin Leontein, Mei Li, Robert L. Cleek, Paul D. Drumheller
  • Patent number: 11077124
    Abstract: A pharmaceutical composition for inhalation comprising R (+) budesonide and one or more bronchodilators, and, optionally, one or more pharmaceutically acceptable excipients is described.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: August 3, 2021
    Assignee: CIPLA Limited
    Inventors: Geena Malhotra, Shrinivas Madhukar Purandare, Amar Lulla
  • Patent number: 10849865
    Abstract: The present invention is directed to pharmaceutical compositions and methods of treating traumatic brain injury (TBI). The invention is also directed to pharmaceutical compositions and methods of treating a transient hypoxic and/or ischemic condition in the central nervous system. More specifically, the present invention is directed to pharmaceutical compositions and methods of reducing the occurrence of neuronal cell death in the central nervous system, such as, reducing the occurrence brain cell death in the hippocampus and/or the cortex.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: December 1, 2020
    Assignee: The University of Montana
    Inventors: David J. Poulsen, Thomas Frederick Rau
  • Patent number: 10780067
    Abstract: Disclosed are methods and topical formulations for treating and/or preventing cell proliferative diseases and disorders including breast cancer and ductal carcinoma is situ (DCIS) using local transdermal therapy (LTT). The disclosed methods typically include administering topically to the breast or breasts of the patient a topical formulation comprising an effective dose of the tamoxifen metabolite, N-desmethyl-4-hydroxytamoxifen (i.e., endoxifen or ENX) for treating breast cancer. The topical formulation may be described as a transdermal formulation and the topical formulation may comprise, consist essentially of, or consist of endoxifen as an active ingredient.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 22, 2020
    Assignee: Northwestern University
    Inventors: Seema Ahsan Khan, Oukseub Lee
  • Patent number: 10709754
    Abstract: The present invention relates to a composition for preventing, ameliorating, or treating hyperuricemia or metabolic disorders related with hyperuricemia comprising an extract of Alpinia oxyphylla as an effective ingredient. Because the extract of Alpinia oxyphylla of the present invention can reduce the uric acid amount in blood of an animal model and is derived from natural products, and the raw materials can be easily obtained, it can be widely used in industries that are related to hyperuricemia or metabolic disorders related with hyperuricemia. It can be effectively used for prevention, amelioration, or treatment of gout or gouty arthritis, in particular.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: July 14, 2020
    Inventors: Dong Seon Kim, Ohn Soon Kim, Yun Mi Lee, Young-Sil Lee, Eun Jung Son
  • Patent number: 10675282
    Abstract: This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: June 9, 2020
    Assignee: VeroScience LLC
    Inventor: Anthony H. Cincotta
  • Patent number: 10016373
    Abstract: The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4?-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: July 10, 2018
    Inventors: Sharon Anavi-Goffer, Juerg Gertsch
  • Patent number: 9981906
    Abstract: The present invention relates to substantially pure metabolites of irara-clomiphene. The invention is also directed to pharmaceutical compositions comprising these metabolites and their use in treating disorders including secondary hypogonadism, type 2 diabetes, elevated cholesterol, elevated triglycerides, wasting, lipodystrophy, female and male infertility, benign prostate hypertrophy, prostate cancer, breast cancer, ovarian cancer and endometrial cancer.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: May 29, 2018
    Assignee: Repros Therapeutics Inc.
    Inventors: Joseph S. Podolski, Ronald D. Wiehle
  • Patent number: 9814687
    Abstract: Formulations for transdermal pharmaceutical compositions including clomiphene-like selective estrogen receptor modulators (C-SERMs) in combination with transdermal penetration enhancers are disclosed. Transdermal pharmaceutical compositions can be designed with various release rates, and are administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency in male hypogonadism or male infertility. Transdermal pharmaceutical compositions include a range of dosage forms, such as, for example solutions, liquid sprays, lotions, emulsions, creams, pastes, and ointments, among other dosage forms that exhibit transdermal properties, and provide transdermal delivery of C-SERMs. Transdermal pharmaceutical compositions will deliver C-SERMs through the skin and directly into the patient's bloodstream, thereby providing high bioavailability of C-SERMs.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: November 14, 2017
    Assignee: Professional Compounding Centers of America
    Inventors: Tsu-I Catherine Wang, Bruce V. Biundo
  • Patent number: 9730890
    Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: August 15, 2017
    Assignee: Mylan Pharmaceuticals, Inc.
    Inventors: Partha S. Banerjee, Imtiaz A. Chaudry, Stephen Pham
  • Patent number: 9708328
    Abstract: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: July 18, 2017
    Assignee: Janssen Sciences Ireland UC
    Inventors: Pierre Jean-Marie Bernard Raboisson, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Kenneth Alan Simmen
  • Patent number: 9538774
    Abstract: Feeding a diet supplemented with DDGS or another supplement containing UFA at a level above a threshold to animals such as swine, cattle, and poultry can have negative effects on carcass fat, certain growth parameters, and meat characteristics. However, if this diet is provided with a second supplement that contains CPFA at specified levels in the diet, the negative effects otherwise expected are wholly or at least partially countered. The invention recommends employing a supplemental source of CPFA between about 0.001% and about 0.5% of the diet by weight. Negative effects on carcass characteristics caused by ractopamine can also be countered by the addition of this amount of at least one source of CPFA in the diet.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: January 10, 2017
    Assignee: Nutriquest, LLC
    Inventors: Chad D Hagen, Steven P Weiss, Wayne Cast, Kenneth W Purser, Ran Song, Dale Green
  • Patent number: 9486419
    Abstract: The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4?-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: November 8, 2016
    Assignee: Ariel-University Research and Development Company
    Inventors: Sharon Anavi-Goffer, Juerg Gertsch
  • Patent number: 9248141
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use for treatment of cardiovascular, vascular, neurological, for wounds and for other indications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication or prevention of hemichannel opening is desirable.
    Type: Grant
    Filed: February 3, 2006
    Date of Patent: February 2, 2016
    Assignee: CoDa Therapeutics, Inc.
    Inventors: Colin R. Green, David L. Becker
  • Patent number: 9176139
    Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: November 3, 2015
    Assignee: Gilead Biologics, Inc.
    Inventors: Victoria Smith, Scott Ogg, Peter Van Vlasselaer, Vivian E. Barry, Derek Marshall, Alison Kay Holzer, Hector Rodriguez, Miho Oyasu, Scott Alan McCauley, Carlos Aurelio Garcia, Donna Hiroko Tokuoka Biermann
  • Patent number: 9145353
    Abstract: A method of preparing (S)-2-amino-5-methoxytetralin hydrochloride[(S)-2-amino-5-methoxyl-1,2,3,4-tetrahydronaphthalene hydrochloride], comprising the steps of: (1) producing a compound (I) by addition-elimination reaction of 5-methoxy-2-tetralone and R-(+)-a-phenylethylamine; (2) producing a compound (II) by reduction reaction of the compound (I) with a reducing agent; and (3) producing a compound (II) hydrochloride by reacting the compound (II) with a salt-forming agent, then carrying out reduction reaction with a palladium-carbon catalyst to produce (S)-2-amino-5-methoxytetralin hydrochloride. The method can significantly increase the yield of (S)-2-amino-5-methoxytetralin hydrochloride with short synthetic path, low preparation cost and less pollution, which is environmentally friendly and is suitable for medical industrialized production. The structural formulae of the compound (I) and the compound (II) are: respectively.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: September 29, 2015
    Assignee: Anhui Kelong Institute of Pharmaceutical
    Inventors: Qingyun Huang, Qingguo Huang, Meixian Lou
  • Publication number: 20150148426
    Abstract: The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 28, 2015
    Inventors: Clas SONESSON, Jonas KARLSSON, Peder SVENSSON
  • Patent number: 9040507
    Abstract: A method for treating an autoimmune disease in a subject includes administering to the subject a therapeutically effective amount of an agent comprising an imidazole, an estrogen receptor agonist, or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: May 26, 2015
    Assignee: Novelmed Therapeutics, Inc.
    Inventor: Rekha Bansal
  • Publication number: 20150141391
    Abstract: The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to mutations in the gene encoding estrogen receptor and their association with responsiveness to estrogen therapies for cancer.
    Type: Application
    Filed: October 14, 2014
    Publication date: May 21, 2015
    Inventors: Arul M. Chinnaiyan, Dan Robinson, Yi-Mi Wu
  • Publication number: 20150140133
    Abstract: A system is described for long-term controlled release delivery of a drug or a therapeutic agent. According to the invention, one or more drugs or therapeutic agents contained in microspheres are mixed with a temperature sensitive hydrogel which is then introduced directly to the desired situs of the drug or therapeutic agent. The temperature sensitive hydrogel may also contain a drug or a therapeutic agent, for example, a pain relieving drug, for a short-term controlled release. The temperature sensitive hydrogel is in liquid state at room temperature, but upon injection, shortly becomes gelatinous. This system is particularly suitable for treatment of diseases, disorders, or conditions, for example, tumors, discogenic back pain, or arthritis, warranting localized administration of a drug or a therapeutic agent. In addition, the specification provides a method for production of a drug- or therapeutic agent-containing microspheres.
    Type: Application
    Filed: December 4, 2014
    Publication date: May 21, 2015
    Inventor: Tae-Hong Lim
  • Publication number: 20150141417
    Abstract: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.
    Type: Application
    Filed: May 14, 2012
    Publication date: May 21, 2015
    Inventors: Qingqi Chen, Rocio Alejandra Lopez, Jonathan Daniel Heller, Amanda Jean Morris
  • Publication number: 20150133562
    Abstract: The present invention provides a novel palatable pharmaceutical composition in the form of aqueous solution of atomoxetine. The oral aqueous solution of this invention will significantly reduce the potently bitter taste of atomoxetine, and further avoid swallow issue for young and elderly patients.
    Type: Application
    Filed: December 19, 2013
    Publication date: May 14, 2015
    Applicant: Eli Lilly and Company
    Inventors: Arup Kumar ROY, Matthew Scott MERMEY
  • Publication number: 20150112116
    Abstract: Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid particulate material. The invention also provides compositions comprising at least one of a tyrosine derivative impregnated with a solid particulate material and a solid particulate material impregnated with a tyrosine derivative.
    Type: Application
    Filed: October 24, 2013
    Publication date: April 23, 2015
    Inventor: STEVEN HOFFMAN
  • Publication number: 20150110735
    Abstract: A centrifugal mixing device can include a shaft assembly that is operably coupled to a motor such that the motor rotates the shaft assembly about a first axis. The devices can further include a turret that is rotatably coupled to the shaft assembly such that the turret rotates about the first axis relative to the shaft assembly. The turret can include a first support, a first canister rotatably coupled to the first support such that the first canister rotates about a second axis, and a second canister rotatably coupled to the first support such that the second canister rotates about a third axis. The turret is configured to rotate about the first axis in a first rotational direction and each of the first and second canisters is configured to rotate about the second and third axes, respectively, in a second rotational direction that is opposite the first rotational direction.
    Type: Application
    Filed: October 22, 2013
    Publication date: April 23, 2015
    Inventor: Steven Hoffman
  • Publication number: 20150094377
    Abstract: The invention generally relates to a molecular classification of disease predisposition and particularly to molecular markers for cancer predisposition and methods of use thereof.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 2, 2015
    Inventors: Kirsten Timms, Brian Allen, Anne-Renee Hartman
  • Patent number: 8993571
    Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: March 31, 2015
    Assignee: Galderma Laboratories, L.P.
    Inventors: Jack A. DeJovin, Isabelle Jean DeJovin
  • Publication number: 20150087718
    Abstract: Provided are compositions and methods for use in polycystic ovary syndrome diagnosis (PCOS). The method involves a sample from a subject for a DENND1A Variant 2 mRNA or DENND1 A Variant 2 protein to make or aid in a diagnosis of PCOS. Also provided are methods for selecting an individual as a candidate for therapy for polycystic ovary syndrome by testing a biological sample from an individual for DENND1 A Variant 2 mRNA or DENND1 A Variant 2 protein and designating the individual as a candidate for the PCOS based on determining DENND1 A Variant 2 mRNA or DENND1 A Variant 2 protein in the sample. Also provided are products for use in aiding diagnosis of PCOS which contain reagents for detecting DENND1 A Variant 2 mRNA or DENND1 A Variant 2 protein, and packaging containing printed material describing use and indications for the product.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 26, 2015
    Inventors: Janette M McAllister, Jerome F Strauss
  • Patent number: 8986664
    Abstract: The invention provides a method for improving hair biology, e.g., hair growth. The method comprises administering to a subject a monoamine oxidase inhibitor and a vasodilator, a zinc salt of a carboxylic acid, a xanthine compound, pyrithione or a salt thereof, saponin, tritapene, crataegolic acid, celastrol, asiatic acid, an inhibitor of 5-alpha-reductase, 1,4-methyl-4-azasteroid, an androgen receptor antagonist, azelaic acid or a derivate thereof, cyclosporin, triiodothyronine, diazoxide, retinoic acid, a prostaglandin analog, aminexil, carnitine tartrate, apigenin, procapil, or adenosine, in an amount effective to achieve a desired effect. The invention further provides a method of reducing or delaying the appearance of an age-related skin imperfection. The method comprises administering to the subject a composition comprising an MAO inhibitor. A kit for improving hair growth also is provided.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: March 24, 2015
    Assignee: The Procter & Gamble Company
    Inventors: Teresa DiColandrea, Robert Scott Youngquist, Sancai Xie, Robert Lloyd Binder, Gary Richard Fuentes, Deborah Lade
  • Publication number: 20150065580
    Abstract: The present invention relates to the field of medicine and particularly relates to the application of fluoxetine to the treatment of depigmentation diseases. Pharmacodynamic tests have demonstrated that fluoxetine has the effects of treating depigmentation diseases especially leukotrichia and vitiligo.
    Type: Application
    Filed: December 5, 2012
    Publication date: March 5, 2015
    Inventors: Jing Shang, Sha Liao, Yu Jin, Xiaoli Tian, Guorui Zhao, Jia Zhou, Qian Wang, Silin Pang
  • Patent number: 8969371
    Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: March 3, 2015
    Assignee: Orexigen Therapeutics, Inc.
    Inventors: Preston Klassen, Kristin Taylor
  • Patent number: 8962016
    Abstract: The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms.
    Type: Grant
    Filed: November 25, 2010
    Date of Patent: February 24, 2015
    Assignee: Wockhardt Ltd.
    Inventors: Prashant Manohar Mandaogade, Venkatesh Madhavacharya Joshi, Saurabh Srivastava, Vinayak Dinkar Kadam, Girish Kumar Jain
  • Publication number: 20150045388
    Abstract: A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a drug to the back of the neck of a human patient at the hairline in close proximity to and under or on the area of skin above the brain stem to provide regional neuro-affective therapy is disclosed.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventor: Ronald AUNG-DIN
  • Publication number: 20150031705
    Abstract: Ophthalmic formulations are provided. The ophthalmic formulations include one or more active agents that act to optimize pupil light reflex while minimizing, or effectively eliminating, any undesired eye redness in response to application thereof. The active agents include, for example, alpha 1 antagonists, such as alpha 1a selective antagonists.
    Type: Application
    Filed: October 14, 2014
    Publication date: January 29, 2015
    Inventor: Gerald Horn
  • Publication number: 20150011643
    Abstract: Administration of monoamine oxidase inhibitors is useful in the prevention and treatment of heart failure and incipient heart failure.
    Type: Application
    Filed: July 15, 2014
    Publication date: January 8, 2015
    Inventors: Fabio DiLisa, Ning Feng, Nina Kaludercic, Nazareno Paolocci
  • Patent number: 8921386
    Abstract: A drug substance with a pharmaceutically acceptable organic acid addition salt of an opioid wherein said organic acid is selected from Structure A: wherein R1-R4 are independently selected from H, alkyl or substituted alkyl of 1-6 carbons, adjacent groups may be taken together to form a cyclic alkyl, cyclic alkyl-aryl, or cyclic aryl moiety; R5 is selected from H, or an alkali earth cation; R6 and R7 are independently selected from H, alkyl of 1-6 carbons, an alkali earth cation, and aryl of 6 to 12 carbons, in a number sufficient to complete the valence bonding of X, and wherein X is selected from nitrogen, oxygen or sulfur; and wherein the drug substance has a morphology selected from amorphous and crystalline.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: December 30, 2014
    Assignee: Pisgah Laboratories, Inc.
    Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol, Michael L. English
  • Patent number: 8920837
    Abstract: The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer which provides pH-independent drug release for a considerable period of time after administration.
    Type: Grant
    Filed: July 3, 2006
    Date of Patent: December 30, 2014
    Assignee: Rubicon Research Private Limited
    Inventors: Pratibha S. Pilgaonkar, Maharukh T. Rustomjee, Anilkumar S. Gandhi, Paras R. Jain, Atul A. Kelkar
  • Publication number: 20140378424
    Abstract: The present invention relates to a method of reducing the body weight of a subject by administering an effective amount of an estrogen receptor modulator (ERM), optionally, in combination with an anti-obesity or weight loss agent.
    Type: Application
    Filed: December 31, 2012
    Publication date: December 25, 2014
    Inventors: Alexey G Ryazanov, Alexander V. Chikunov
  • Publication number: 20140371177
    Abstract: A method of treating cancer, inflammatory disease, and autoimmune disease by administering to a subject in need thereof an effective amount of one or more 1,5-dipenylpenta-1,4-dien-3-one compounds. The compounds feature either or both of the phenyl rings being substituted with hydroxyl, diethyl(2-alkoxyethyl)amine, 1-(2-alkoxyethyl)piperidine, sulfonate, phosphinate, or phosphate.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 18, 2014
    Inventors: Charles C-Y Shih, Toshio Kitamura, Qian Shi, Toshiyuki Kawashima, Hui-Kang Wang
  • Publication number: 20140348958
    Abstract: A compound of formula (I), a positional or structural isomer thereof, or a pharmaceutically acceptable base addition salt or acid addition salt thereof, use thereof as a medicament, in particular an anticancer medicament.
    Type: Application
    Filed: September 12, 2012
    Publication date: November 27, 2014
    Inventors: Pierre Chalard, Florence Caldefie-Chezet, Laetitia Delort, Kirti Patel
  • Patent number: 8884061
    Abstract: The invention provides compounds of the formula: or a pharmaceutically acceptable salt thereof, where m, n, R1, R2, R3 R4, R5, R6, R7 are those defined herein. The invention also provides pharmaceutical compositions comprising a compound of the invention, methods for using compounds and/or pharmaceutical compositions of the invention, and methods for synthesizing compounds of the invention.
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: November 11, 2014
    Assignee: Colorado State University Research Foundation
    Inventors: Michio Kurosu, Dean Calvin Crick
  • Publication number: 20140322305
    Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.
    Type: Application
    Filed: July 10, 2014
    Publication date: October 30, 2014
    Inventor: John Daniel Dobak
  • Publication number: 20140323527
    Abstract: The present invention relates generally to the field of therapeutic treatment and compounds having utility therefor, in particular the therapy or management of conditions associated with excessive, unwanted or undesirable sodium ion passage through cellular membranes via voltage-gated sodium channels. In one embodiment the invention is concerned with the treatment of neuropathic pain. The invention contemplates to aryloxy-substituted amines, as sodium channel blockers or modulators. In further embodiments, the invention also relates to compounds which may advantageously have dual sodium channel blocker/modulating and antioxidative (free-radical scavenging) effects. Methods for their manufacture and compositions containing the compounds are also contemplated.
    Type: Application
    Filed: March 24, 2014
    Publication date: October 30, 2014
    Inventor: Bevyn JARROTT
  • Publication number: 20140323530
    Abstract: Provided are amine derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
    Type: Application
    Filed: March 26, 2014
    Publication date: October 30, 2014
    Applicant: Acucela Inc.
    Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Feng Hong, Thomas L. Little, Ryo Kubota
  • Publication number: 20140303256
    Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of blood-brain barrier disorder comprising fluoxetine as an active ingredient. More particularly, fluoxetine inhibits the expressions of matrix metalloproteinase(MMP)-2, MMP-9, and MMP-12, which are reported to be related to blood-brain barrier (BBB) disruption and inflammatory reaction after spinal cord injury, specifically inhibits the activations of MMP-2 and MMP-9, inhibits the decomposition of ZO-1, the most representative tight junction protein, so as to maintain tight junction between endothelial cells and to protect blood-brain barrier thereby, inhibits the increase of blood-brain barrier permeability, and inhibits the expressions of chemoattractants of blood cells, such as CXCL-1, CXCL-2, CCL-2, CCL-3 and CCL-4 so as to reduce inflow of blood into spinal cord and recover exercise function which has been deteriorated by spinal cord injury.
    Type: Application
    Filed: October 19, 2012
    Publication date: October 9, 2014
    Inventors: Tae Young Yune, Tae Hwan Oh, Hyung Hwan Baik, Jee Youn Lee
  • Patent number: 8853279
    Abstract: The invention relates to a method for determining whether a patient suffering from a condition that is susceptible to treatment with a compound that activates the brain serotonin system is susceptible or resistant to treatment with the compound. The method includes establishing whether the patient is a pre-adult, a transition age patient, or an adult and observing whether the genome of the patient contains at least one copy of a BDNF allele having a genetic alteration. The method further includes correlating the presence of the allele containing the genetic alteration with susceptibility or resistance of the patient to the treatment with the compound, wherein a pre-adult patient containing the genetic alteration is correlated as being susceptible to the treatment; a transition age patient containing the genetic alteration is correlated as being susceptible or resistant to the treatment; and an adult patient containing the genetic alteration is correlated as being resistant to the treatment.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: October 7, 2014
    Assignee: Cornell University
    Inventors: Francis S. Lee, Barbara Hempstead, James Kocsis, Kevin Bath
  • Publication number: 20140296197
    Abstract: Combinations comprising (a) a ?2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventors: Jordi GRAS ESCARDO, Jesus LLENAS CALVO, Hamish RYDER, Pio ORVIZ DIAZ
  • Publication number: 20140286945
    Abstract: Disclosed herein is a new and improved therapy for the treatment of diseases including cancer, which comprises the step of altering cell membrane lipid composition by treating a cancer cell with an enzyme inhibitor which inhibits enzymes regulating the cholesterol biosynthetic pathway. The method may also be employed in combination with existing chemotherapeutic agents to combat the drug resistance and enhance the therapeutic efficacy of conventional therapy.
    Type: Application
    Filed: October 22, 2012
    Publication date: September 25, 2014
    Applicant: The Curators of the University of Missouri
    Inventors: Carl Freter, Indira Benakanakere
  • Patent number: 8841347
    Abstract: The subject of the invention is a group of new derivatives of aminoalkanols, more specifically [(phenoxy)alkyl]aminoalkanols and [(phenoxy)acyl] aminoalkanols, their method of obtaining and their use for production of a medicine which is used in the prophylaxis, prevention and/or treatment of diseases or symptoms having neurological background and for production a medicine with anticonvulsant activity, which is used in seizures of various origin, also in the limbic system, in myoclonic or sound-induced seizures, in psychomotor epilepsy, as well as relieving neuropathic or inflammatory pain.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: September 23, 2014
    Assignees: Uniwersytet Jagiellonski
    Inventors: Henryk Marona, Anna Waszkielewicz, Katarzyna Kiec-Kononowicz
  • Patent number: 8840923
    Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: September 23, 2014
    Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
    Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla, Leonardo Marchitto, Lorella Ragni
  • Patent number: 8829037
    Abstract: The present disclosure describes compositions which improve visual acuity and to methods for their use.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: September 9, 2014
    Inventor: Anant Sharma